Recurrent Lung Adenocarcinoma: Clinical Trials

5 trials for Recurrent Lung Adenocarcinoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 active not recruiting, 2 completed, 1 terminated. 4 Phase 2, 1 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 24Active not recruiting 2, Completed 2
Phase 11Completed 1
Phase 31Terminated 1

Follow Recurrent Lung Adenocarcinoma: new trials by email Literature Review of Recurrent Lung Adenocarcinoma trials Research Report on Recurrent Lung Adenocarcinoma

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer
Pembrolizumab, Pemetrexed, Carboplatin - Metastatic Lung Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma
Phase 2Active not recruitingAlliance for Clinical Trials in Oncology1012020-11-162026-10-08
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
Rucaparib - Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation
Phase 2CompletedSWOG Cancer Research Network642019-04-162025-05-21
Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung Cancer
Nivolumab, Stereotactic Body Radiation Therapy - Lung Atypical Carcinoid Tumor, Lung Neuroendocrine Neoplasm
Phase 2Active not recruitingM.D. Anderson Cancer Center1402017-06-262026-06-22
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
Trametinib, Erlotinib - Lung Adenocarcinoma, Lung Cancer
Phase 1 / Phase 2CompletedMemorial Sloan Kettering Cancer Center242017-03-012024-04-02
S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
Bevacizumab, Carboplatin, Cetuximab - Recurrent Large Cell Lung Carcinoma, Recurrent Lung Adenocarcinoma
Phase 3TerminatedSWOG Cancer Research Network13332009-07-152023-05-23

Narrower conditions

Adenocarcinoma of Lung (5)  ·  Lung Neoplasms (4)  ·  Carcinoma, Non-Small-Cell Lung (3)  ·  Adenocarcinoma, Bronchiolo-Alveolar (1)  ·  Carcinoma, Neuroendocrine (1)

Broader conditions

Adenocarcinoma (5)  ·  Carcinoma (5)  ·  Neoplasms (5)  ·  Neoplasms by Histologic Type (5)  ·  Neoplasms by Site (5)  ·  Neoplasms, Glandular and Epithelial (5)  ·  Respiratory Tract Neoplasms (5)  ·  Thoracic Neoplasms (5)  ·  Lung Diseases (4)  ·  Respiratory Tract Diseases (4)  ·  Bronchial Neoplasms (3)  ·  Carcinoma, Bronchogenic (3)  ·  Lung Neoplasms (1)  ·  Neoplasms, Germ Cell and Embryonal (1)  ·  Neoplasms, Nerve Tissue (1)

Interventions

Carboplatin (2)  ·  Bevacizumab (1)  ·  Cetuximab (1)  ·  Disulfides (1)  ·  Erlotinib Hydrochloride (1)  ·  Geriatric Assessment (1)  ·  Immunoglobulin G (1)  ·  Nivolumab (1)  ·  Paclitaxel (1)  ·  Pemetrexed (1)  ·  Radiosurgery (1)  ·  Taxes (1)  ·  pembrolizumab (1)  ·  rucaparib (1)  ·  trametinib (1)

Sponsors

SWOG Cancer Research Network (2)  ·  Alliance for Clinical Trials in Oncology (1)  ·  M.D. Anderson Cancer Center (1)  ·  Memorial Sloan Kettering Cancer Center (1)

Countries

United States (5)  ·  Mexico (1)

Top investigators

Aminah Jatoi, MD (1)  ·  Helena Yu, MD (1)  ·  Joe Y Chang (1)  ·  Jonathan W Riess (1)  ·  Roy Herbst (1)

Results publications

PMID 29169877, PMID 34753703, PMID 37478883, PMID 42161344

NIH funding

U10CA180888 (2), U10CA032102 (1), UG1CA189823 (1)